Skip to main content
Erschienen in: Medical Oncology 10/2016

01.10.2016 | Short Communication

Association between polymorphisms in xenobiotic detoxification-related genes with prognosis of epithelial ovarian cancer

verfasst von: Juliana Carron, Angelo Borsarelli Carvalho Brito, Ana Carolina Mourão Torelli, Cristiane Oliveira, Sophie Françoise Mauricette Derchain, Carmen Silvia Passos Lima, Gustavo Jacob Lourenço

Erschienen in: Medical Oncology | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

This study aimed to evaluate whether GSTM1 and GSTT1 (presents or nulls), GSTP1 c.313A>G and NQO2 c.-102A>C polymorphisms, involved in xenobiotic detoxification pathways, alter outcomes of epithelial ovarian cancer (EOC) patients. DNA from 84 EOC patients diagnosed at the University of Campinas Academic Hospital from January 1995 and July 2007 was analyzed by polymerase chain reaction and restriction fragment length polymorphism assays. The prognostic impact of genotypes of polymorphisms on progression-free survival and overall survival (OS) of EOC patients was examined using the Kaplan–Meier probability estimates and univariate and multivariate Cox proportional hazard ratio (HR) regression analyses. The significant results of Cox analyses were validated using a bootstrap resampling study (1000 replications). At 60 months of follow-up, lower OS was seen in patients with GSTT1 null genotype (50.0 vs. 76.7 %, P = 0.02) compared with the other genotype (Kaplan–Meier estimate). This outcome remained the same in univariate Cox analysis (HR 2.22, P = 0.02). After multivariate Cox analysis, patients with GSTT1 null (HR 2.11, P = 0.04, P bootstrap = 0.04) and NQO2 AA (HR 2.13, P = 0.03, P bootstrap = 0.04) genotypes were under greater risks of progressing to death when compared with those with others genotypes. Our data suggest, for the first time, that inherited abnormalities in xenobiotic detoxification pathway related to GSTT1 and NQO2 c.-102A>C polymorphisms act as independent prognostic factors for OS of EOC patients.
Literatur
2.
Zurück zum Zitat Patch AM, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521(7553):489–94.CrossRefPubMed Patch AM, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521(7553):489–94.CrossRefPubMed
3.
Zurück zum Zitat Pereira D, et al. Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile. Eur J Clin Pharmacol. 2016;72(5):545–53.CrossRefPubMed Pereira D, et al. Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile. Eur J Clin Pharmacol. 2016;72(5):545–53.CrossRefPubMed
4.
Zurück zum Zitat Beeghly A, et al. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol Oncol. 2006;100(2):330–7.CrossRefPubMed Beeghly A, et al. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol Oncol. 2006;100(2):330–7.CrossRefPubMed
5.
Zurück zum Zitat Nagle CM, et al. The role of glutathione-S-transferase polymorphisms in ovarian cancer survival. Eur J Cancer. 2007;43(2):283–90.CrossRefPubMed Nagle CM, et al. The role of glutathione-S-transferase polymorphisms in ovarian cancer survival. Eur J Cancer. 2007;43(2):283–90.CrossRefPubMed
6.
Zurück zum Zitat Kim HS, et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol. 2009;113(2):264–9.CrossRefPubMed Kim HS, et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol. 2009;113(2):264–9.CrossRefPubMed
7.
Zurück zum Zitat Khrunin AV, et al. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenom J. 2010;10(1):54–61.CrossRef Khrunin AV, et al. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenom J. 2010;10(1):54–61.CrossRef
8.
9.
Zurück zum Zitat Chen S, et al. Structure-function studies of DT-diaphorase (NQO1) and NRH: quinone oxidoreductase (NQO2). Free Radic Biol Med. 2000;29(3–4):276–84.CrossRefPubMed Chen S, et al. Structure-function studies of DT-diaphorase (NQO1) and NRH: quinone oxidoreductase (NQO2). Free Radic Biol Med. 2000;29(3–4):276–84.CrossRefPubMed
10.
Zurück zum Zitat Yu KD, et al. Functional polymorphisms, altered gene expression and genetic association link NRH:quinone oxidoreductase 2 to breast cancer with wild-type p53. Hum Mol Genet. 2009;18(13):2502–17.CrossRefPubMed Yu KD, et al. Functional polymorphisms, altered gene expression and genetic association link NRH:quinone oxidoreductase 2 to breast cancer with wild-type p53. Hum Mol Genet. 2009;18(13):2502–17.CrossRefPubMed
11.
Zurück zum Zitat Howells RE, et al. Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer. Clin Cancer Res. 1998;4(10):2439–45.PubMed Howells RE, et al. Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer. Clin Cancer Res. 1998;4(10):2439–45.PubMed
12.
Zurück zum Zitat Lallas TA, et al. The glutathione S-transferase M1 genotype in ovarian cancer. Cancer Epidemiol Biomark Prev. 2000;9(6):587–90. Lallas TA, et al. The glutathione S-transferase M1 genotype in ovarian cancer. Cancer Epidemiol Biomark Prev. 2000;9(6):587–90.
13.
Zurück zum Zitat Morari EC, et al. Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients. J Cancer Res Clin Oncol. 2006;132(8):521–8.CrossRefPubMed Morari EC, et al. Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients. J Cancer Res Clin Oncol. 2006;132(8):521–8.CrossRefPubMed
14.
Zurück zum Zitat Kurman RJ, et al. WHO classification of tumours of female reproductive organs. 4th ed. Lyon: IARC Press; 2014. Kurman RJ, et al. WHO classification of tumours of female reproductive organs. 4th ed. Lyon: IARC Press; 2014.
15.
Zurück zum Zitat Prat J. FIGO, Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124(1):1–5.CrossRefPubMed Prat J. FIGO, Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124(1):1–5.CrossRefPubMed
16.
Zurück zum Zitat Prahm KP, et al. The prognostic value of dividing epithelial ovarian cancer into type I and type II tumors based on pathologic characteristics. Gynecol Oncol. 2015;136(2):205–11.CrossRefPubMed Prahm KP, et al. The prognostic value of dividing epithelial ovarian cancer into type I and type II tumors based on pathologic characteristics. Gynecol Oncol. 2015;136(2):205–11.CrossRefPubMed
17.
Zurück zum Zitat Arruda VR, et al. Increased risk for acute myeloid leukaemia in individuals with glutathione S-transferase mu 1 (GSTM1) and theta 1 (GSTT1) gene defects. Eur J Haematol. 2001;66(6):383–8.CrossRefPubMed Arruda VR, et al. Increased risk for acute myeloid leukaemia in individuals with glutathione S-transferase mu 1 (GSTM1) and theta 1 (GSTT1) gene defects. Eur J Haematol. 2001;66(6):383–8.CrossRefPubMed
18.
Zurück zum Zitat Hohaus S, et al. Glutathione S-transferase P1 genotype and prognosis in Hodgkin’s lymphoma. Clin Cancer Res. 2005;11(6):2175–9.CrossRefPubMed Hohaus S, et al. Glutathione S-transferase P1 genotype and prognosis in Hodgkin’s lymphoma. Clin Cancer Res. 2005;11(6):2175–9.CrossRefPubMed
20.
Zurück zum Zitat Fagerholm R, et al. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet. 2008;40(7):844–53.CrossRefPubMed Fagerholm R, et al. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet. 2008;40(7):844–53.CrossRefPubMed
Metadaten
Titel
Association between polymorphisms in xenobiotic detoxification-related genes with prognosis of epithelial ovarian cancer
verfasst von
Juliana Carron
Angelo Borsarelli Carvalho Brito
Ana Carolina Mourão Torelli
Cristiane Oliveira
Sophie Françoise Mauricette Derchain
Carmen Silvia Passos Lima
Gustavo Jacob Lourenço
Publikationsdatum
01.10.2016
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 10/2016
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-016-0819-8

Weitere Artikel der Ausgabe 10/2016

Medical Oncology 10/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.